Form D · Pharmaceuticals
Enumeral Biomedical Holdings, Inc.
Cambridge, MA · CIK 0001561551
Offering snapshot reported May 25, 2017 · SEC filing
- Reported sold
- $668K Offering amount: $3.6M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 25, 2017 | Initial | $668,000 | No comparison | 15 | SEC filing |
| Dec 15, 2016 | Initial | $3,431,500 | No comparison | 108 | SEC filing |
| Aug 2, 2016 | Initial | $3,038,256 | No comparison | 84 | SEC filing |
| Aug 13, 2014 | Initial | $25,150,000 | No comparison | 79 | SEC filing |
| Aug 13, 2014 | Initial | $21,549,510 | No comparison | 253 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $66.8K
- Finders' fees
- $0
- Form D file number
- 021-287510
Total offering amount includes additional $600,000 of securities that may be sold pursuant to oversubscriptions
Cash compensation equal to 10% of the gross proceeds of the offering.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| GP NURMENKARI INC. | 153480 | |
| Katalyst Securities LLC | 112494 |
Source: Form D, filed May 25, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Derek Brand | Executive |
| Barry Buckland | Director |
| Barry Buckland, Ph.D. | Director |
| Robert J. Easton | Director |
| Wael Fayad | Director, Executive |
| Anhco Nguyen | Executive |
| Anhco Nguyen, Ph.D. | Executive |
| Allan P. Rothstein | Director |
| John J. Rydzewski | Director, Executive |
| Kevin G. Sarney | Executive |
| Paul J. Sekhri | Director |
| Arthur H. Tinkelenberg | Director, Executive |
| Arthur H. Tinkelenberg, Ph.D. | Director |
| Robert L. Van Nostrand | Director |
| Daniel B. Wolfe | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
200 Cambridgepark Drive, Suite 2000
Cambridge, MA, 02140
Cambridge, MA, 02140